SEC Form 4 Filing for Amylyx Pharmaceuticals, Inc.

This filing details a transaction by Joshua B. Cohen, Co-Chief Executive Officer and Director of Amylyx Pharmaceuticals, Inc. On September 10, 2026, Cohen disposed of 29,545 shares of Common Stock with a weighted average price of $32.1557 and 919 shares of Common Stock with a weighted average price of $33.1488. These sales were made to cover tax withholding obligations related to the vesting of performance stock units. The sales were automatic and not at Cohen's discretion. Following these transactions, Cohen directly owns 3,613,123 shares of common stock.